Drugs / FMX-101
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04070755 | Sep → Nov 2016 | — | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04052711 | Sep → Nov 2016 | — | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04064125 | Sep 2016 | — | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04070742 | Aug → Sep 2016 | — | Vyne Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMX-101 | “A 4-Day, Randomized, Controlled Study to Evaluate the Phototoxicity Potential of FMX-101, 4% in Healthy Volunteers” NCT04070742 ↗ |